1716-P: Menopausal Stage and Weight Outcomes with Orforglipron vs. Placebo: Post Hoc Subgroup Analysis from ATTAIN-1 and ATTAIN-2
ANDREEA CIUDIN, Beverly Tchang, AMELIA J. BALMAIN, SUZANNE KLISE et autres
Introduction and Objective: Obesity, a chronic progressive disease, is exacerbated by estrogen deficiency during menopause. Orforglipron (OFG), an oral small-molecule, non-peptide GLP-1 receptor agonist, has demonstrated significant body weight (BW) reductions in ATTAIN-1 and -2. This post-hoc analysis evaluates OFG’s effect on …
0 citations
Diabetes